Actelion Pharmaceuticals Ltd

Hoffmann-la Roche Inc.

Idorsia Pharmaceuticals Ltd

Other

Daniel Bur

Corinna Grisostomi

Sylvia Richard-Bildstein

Olivier Corminboeuf

Sylvaine Cren

Lubos Remen

Thomas Weller

Walter Fischli

Johannes Aebi

Henrietta Dehmlow

Alexander Chucholowski

Eric Vieira

Martin Bolli

Christoph Boss

Wolfgang Wostl

Thierry Sifferlen

Oliver Nayler

Eric Argirios Kitas

Volker Breu

Ulrike Obst

Christian N Hubschwerlen

Marcel Muller

Heinz Stadler

Martine Clozel

Michel Therien

Alfred Binggeli

Claus Mueller

Boris Mathys

Georges Hirth

Daniel Dube

Hans Peter Wessel

Markus Gude

Xavier Leroy

Olivier Bezencon

Jean-Philippe Surivet

Michael Scherz

Cornelia Zumbrunn-Acklin

John Gatfield

Cornelia Zumbrunn

Julien Pothier

Maurice Wilhelm

Christian Oefner

Hans-Peter Marki

Rolf Guller

Magali Vercauteren

Richard Welford

Georg Rueedi

Heinz Fretz

David Lehmann

John Scheigetz

Davide Pozzi

Sabine Wallbaum

Thierry Kimmerlin

Bernd Michael Loeffler

Cornelia Zumbrunn Acklin

Philippe Panchaud

Dan McKay

Dwight MacDonald

Hans-Peter M&auml;rki

Denise Blum

Austin Chih-Yu Chen

Carina Lotz-Jenne

Naomi Tidten-Luksch

Oliver Corminboeuf

Walter Fiśchli

David Powell

Joerg Velker

Hans-Peter Weber

Christian Hubschwerlen

Sylvia Richard

The present invention relates to compounds of Formula (I) wherein Ar, R, R, R, and Rare as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of Formula (I), and especially to their use as Galectin-3 inhibitors.

(2-acetamidyl)thio-beta-D-galactopyranoside derivatives

The present invention relates to compounds of Formula (I) wherein Ar, Ar, R, R, and Rare as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of Formula (I), and especially to their use as Galectin-3 inhibitors.

(Hetero)aryl-methyl-thio-beta-D-galactopyranoside derivatives

The present invention relates to compounds of Formula (I) inhibiting indoleamine 2,3-dioxygenase (IDO) and/or tryptophan 2,3-dioxygenase (TDO) enzymes. Further, their synthesis and their use as medicaments in inter alia cancer is disclosed. 

Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase

The present invention relates to compounds of the formula (I) wherein R, R, R, R, and X are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), to methods for the preparation of such compounds of formula (I), and especially to their use as TPH modulators.

Tricyclic imidazole compounds as inhibitors of tryptophan hydroxylase

The present invention relates to compounds of the formula (I) wherein R, R, R, R, R, and X are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), to methods for the preparation of such compounds of formula (I), and especially to their use as TPH modulators.

Tricyclic piperidine compounds

The invention relates to hydroxylated aminotriazole derivatives of formula (I), wherein Q, R, R, Rand Rare as defined in the description, their preparation and their use as pharmaceutically active compounds.

Hydroxylated aminotriazole derivatives as ALX receptor agonists

The invention relates to a method for preparing linear polymers having an amide end or having a star architecture comprising an amide core, by means of a ring opening using lactide and glycolide monomers or a lactide monomer ring in the presence of a catalyst, wherein the method includes the steps of: (i) reacting the excess monomer(s) with an initiator in a solvent, said initiator being selected from among an amine and an amino alcohol, given that the initiator has at least one primary or secondary amine function; (ii) adding a catalyst, said catalyst being a non-nucleophilic base and including at least one neutral sp2 nitrogen atom; and (iii) neutralizing the reaction mixture. Said novel method is particularly advantageous in that it can be easily monitored and enables better modulation of the polymers, and thus of the properties thereof, than the methods of the prior art. The invention also relates to novel polymers that are obtainable by means of said method.

Bridged Spiro[2.4]heptane ester derivatives

The invention relates to oxazolyl-methylether derivatives of formula (I), wherein R, R, R, Rand Rare as defined in the description, their preparation and their use as pharmaceutically active compounds.

Oxazolyl-methylether derivatives as ALX receptor agonists

The invention relates to oxazole and thiazole derivatives of formula (I), wherein A, E, X, Rand Rare as defined in the description, their preparation and their use as pharmaceutically active compounds. 

Oxazole and thiazole derivatives as ALX receptor agonists

The invention relates to fluorinated aminotriazole derivatives of formula (I), wherein A, Rand Rare as defined in the description, their preparation and their use as pharmaceutically active compounds. 

Fluorinated aminotriazole derivatives

The present invention relates to bridged spiro[2.4]heptane derivatives of formula (I), wherein W, Y, Z, Rand Rare as defined in the description, their preparation and their use as pharmaceutically active compounds as ALX receptor and/or FPRL2 agonists for the treatment of inflammatory and obstructive airways diseases. 

Bridged spiro [2.4] heptane derivatives as ALX receptor and/or FPRL2 agonists

The invention relates to aminotriazole derivatives of formula (I), wherein A, E, Rand Rare as defined in the description, their preparation and their use as pharmaceutically active compounds.

Aminotriazole derivatives as ALX agonists

The invention relates to aminopyrazole derivatives of formula (I), wherein A, E, Rand Rare as defined in the description, their preparation and their use as pharmaceutically active compounds.

Aminopyrazole derivatives

The invention relates to compounds of formula (I) wherein U, V, W, X, R1, R2, R3, R4, R5, R6, A, B, D, E, G, m, and n are as defined in the description, to pharmaceutically acceptable salts of such compounds for use in the manufacture of a medicament for the prevention or treatment of a bacterial infection. Certain compounds of formula (I) are new and are also part of this invention. 

Oxazolidinone antibiotics

The invention relates to novel bicyclononene derivatives of Formula (I); and the use thereof as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as inhibitors of renin. 

Bicyclononene derivatives

Growing community of inventors

Therwil, Switzerland

Daniel Bur